ibrutinib
janssen,abbvie
['ibru', 'lymsm', 'cll']
#eha2022 | alessandra ferrajoli investigated chemoimmunotherapy + targeted therapy in cll. in 45 pts treated, the 5-year pfs and os were 97.7% and 97.8%, respectively. after a median follow-up of 44.2 mos after discontinuing ibrutinib, 6 pts had an mrd recurrence #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm